About
Technology
Issues
FAQ
Links
Official Page
Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.